The batch was only distributed to and sold in Switzerland, and the recall is limited to the specific batch and to Switzerland...The companies will collaborate to advance the potential companion diagnostic, originally developed by Lilly

The Cell Therapy Catapult, which focuses on the development of the UK cell therapy industry, said it will work with London-based GlaxoSmithKline plc to explore potential collaborations in a range of areas relevant to the development of cell therapies, from research projects to technical and regulatory strategy

In addition to the stock investment, Aradigm may receive up to $25 million in development milestones, along with tiered royalties...Baxter said it will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014...Other data demonstrated that pharmacological inhibition of Usp14 by the company's small-molecule inhibitors stimulated degradation of the proteins in cell, neuron and brain slice models, suggesting the compounds' potential in a number of

The company plans to move ASM-024 into a Phase II trial in COPD later this year...His contributions to the field of oncology include more than 20 compounds brought into development, including the recently approved anticancer drugs Xalkori (crizotinib) and Inlyta (axitinib), discovered at Pfizer where O'Connor served as the global research therapeutic area head for oncology...Relmada is seeking to move LevoCap through approval using the 505(b)(2) pathway. (See BioWorld Today, Aug. 24, 2012

In addition to RA and Crohn's, the pharma may develop GLPG0634 in psoriasis, irritable bowel syndrome and lupus, mirroring the path by which the label on its blockbuster Humira (adalimumab) was expanded beyond RA. (See BioWorld Today, March 1, 2012, and Jan. 3, 2013...SciClone agreed to make additional payments of $10 million if Zensun receives approval of Neucardin by subcutaneous infusion, and further indications and improved product forms could result in additional payments...Prior to the

Fenofibrate Tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients with primary hypercholesterolemia or mixed dyslipidemia

The Wilmington, Del.-based firm, however, has countered that somewhat with updated data from the pivotal COMFORT 1 and COMFORT 2 studies that have demonstrated an improvement in survival, news that no doubt helped to boost sales...Longer-term follow-up beyond the 24 weeks may be needed to tease out any differences," he wrote in a research note, adding that "clear demonstration of a survival benefit" could increase its threat to Jakafi

Evotec will work to specifically target peptidoglycan biosynthesis, and will be responsible for commercialization of assets resulting from the collaboration...to produce and supply 123I-labeled NAV5001 for Navidea's late-phase clinical trials...Compared to the placebo group, animals treated with WF10 showed a reduction of the degree of symptoms

Mission Bay Capital committed to fund up to $500,000 per company...The company plans to use proceeds to repurchase common stock and for general corporate purposes, including the repayment of outstanding commercial paper borrowings and upcoming debt maturities

Common stock in Fibrocell Science Inc., of Exton, Pa., has been approved for listing on the NYSE Market, to commence trading on May 17, under the ticker symbol FCSC...Genfit SA, of Lille, France, said GFT505 reduced a new component of cardiovascular risk, remnant cholesterol, contained in lipid particles other than LDL and HDL...In the GFT505-209-4 study, the effect of GFT505 on measured remnant cholesterol was -24 percent (p = 0.0046) compared to the placebo group after 28 days of treatment

Quintiles will also contribute to Merck Serono's future trial design process

Prior to the approval of Nymalize, nimodipine was available only in gel capsule form...The company expects to complete the trial in the first half of 2014. (See BioWorld Today, Dec. 20, 2012...distribution rights to the drug, a next-generation micellar diblock co-polymeric paclitaxel formulation, from Samyang

Even after the news broke Monday – and the Theravance share price (NASDAQ:THRX) gained more than 14 percent to hit $40 – the entire company was still only valued at $3.94 billion...Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307

Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA granted priority review to its new drug application for simeprevir (TMC435), an NS3/4A protease inhibitor for once-daily administration with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease...Valeant Pharmaceuticals International Inc., of Laval, Quebec, has provided additional information related to the proposal to continue

Kinnovata plans to develop, manufacture and commercialize respiratory products for China and other regional Asian markets, initially exploiting Vectura's Clickhaler and Duohaler dry powder inhaler (DPI) technology platforms in asthma and chronic obstructive pulmonary disease...KingYork is expected to hold a 50 percent equity share, with Vectura holding 35 percent and Zendex and partners holding 15 percent

Even after the news broke Monday – and the Theravance share price (NASDAQ:THRX) gained more than 14 percent to hit $40 – the entire company was still only valued at $3.94 billion...Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307

We note that an acquisition of Warner could potentially offer a tax strategy as Warner has a lower tax rate...Regeneron waived its right to opt in on canakinumab and, instead, is entitled to sales royalties

formed a joint venture to commercialize Vectibix (panitumumab) in China...The split is intended to increase the per-share trading price of the common stock to satisfy the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market

rights to market Pertzye (pancrelipase) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis...The board is recommending that shareholders approve the arrangement resolution, which is intended, among other goals, to improve Mirati's ability to attract funding in the larger U.S